[Form 4] ABBVIE INC. Insider Trading Activity

Rhea-AI Filing Summary

Azita Saleki-Gerhardt, Executive Vice President and Chief Operations Officer of AbbVie Inc. (ABBV), reported transactions on 08/12/2025 showing she exercised employee stock options and simultaneously sold the resulting shares. She acquired 42,370 shares through exercise at a reported exercise price of $54.86 per share and sold 42,370 shares the same day at a weighted-average sale price of $198.42 per share. Following these transactions, her reported direct beneficial ownership decreased from 219,662 shares to 177,292 shares. The Form 4 notes 2,647 shares are held in an AbbVie savings program and 3,873 shares are held by her spouse (for which she disclaims beneficial ownership). The transactions were reported by an attorney-in-fact and the filing includes an explanatory footnote that the sale prices reported represent a range of prices between $198.34 and $198.58.

Positive

• None.

Negative

• Insider sale of 42,370 shares reported on 08/12/2025, reducing direct beneficial ownership from 219,662 to 177,292 shares
• Shares sold at weighted-average $198.42 (range $198.34–$198.58) on the same day as option exercise, indicating insider liquidity

Insights

Financial Analyst

TL;DR: Insider exercised options at $54.86 and sold the shares same day at ~ $198.42, reducing direct holdings by 42,370 shares.

This Form 4 documents a routine option exercise and concurrent sale by a senior officer. The exercise converted outstanding employee stock options into 42,370 common shares at the stated exercise price of $54.86 per share, and those shares were sold on the same date at a weighted-average price of $198.42. Post-transaction direct beneficial ownership is reported as 177,292 shares. The filing also discloses small indirect holdings in a savings program (2,647 shares) and shares held by the reporting person’s spouse (3,873), which the reporting person disclaims. For investors, the filing is a clear, contemporaneous disclosure of insider liquidity but does not provide additional company-operating information.

Corporate Governance Expert

TL;DR: Transaction is a standard exercise-and-sale by a named officer; disclosure appears complete with explanatory footnotes.

The filing identifies the reporting person as ABBV’s EVP and Chief Operations Officer and includes required explanations: the exercise was pursuant to the AbbVie 2013 Incentive Stock Program and became exercisable in prior annual increments. The Form 4 includes a footnote disclosing the weighted-average sale price range and offers to provide detailed per-price sale information upon request. The signature is by an attorney-in-fact. From a governance and compliance perspective, the disclosure is appropriately detailed and follows Section 16 reporting norms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SALEKI-GERHARDT AZITA

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF OPERATIONS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	08/12/2025		M		42,370	A	$54.86	219,662	D
Common Stock, $0.01 par value	08/12/2025		S		42,370	D	$198.42(1)	177,292	D
Common Stock, $0.01 par value								2,647(2)	I	Profit sharing trust
Common Stock, $0.01 par value								3,873(3)	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy)	$54.86	08/12/2025		M			42,370	(4)	02/17/2026	Common Stock	42,370	$54.86	0	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.34 to $198.58, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. Balance in AbbVie Savings program as of August 1, 2025. Balance includes shares acquired pursuant to a dividend reinvestment feature.

3. The reporting person disclaims beneficial ownership of all securities held by her spouse.

4. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,124 on February 18, 2017, 14,123 on February 18, 2018, and 14,123 on February 18, 2019.

	/s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did ABBV insider Azita Saleki-Gerhardt report on 08/12/2025?

She exercised employee stock options to acquire 42,370 shares at $54.86 per share and sold 42,370 shares the same day at a weighted-average price of $198.42.

How did the Form 4 affect Azita Saleki-Gerhardt's ownership in ABBV?

Her reported direct beneficial ownership decreased from 219,662 shares to 177,292 shares following the transactions.

Are there any indirect holdings disclosed for Azita Saleki-Gerhardt in this filing?

Yes. The filing reports 2,647 shares in the AbbVie savings program and 3,873 shares held by her spouse (the reporting person disclaims beneficial ownership of the spouse-held shares).

What option plan governed the exercised options?

The options were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program, and the filing notes the options became exercisable in prior annual increments.

Who signed the Form 4 filing?

The filing is signed by T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt on 08/14/2025.